Biophysics and Beyond

The laboratory diagnosis of autoimmune diseases is a complex and multi-stage process. The non-specific nature of clinical manifestations makes early diagnosis difficult. Therefore, the detection of autoantibodies constitutes one of the main pillars of diagnostics. The modern approach is based on the sequential and integrative application of screening and confirmation stages. Indirect immunofluorescence is widely used as the gold standard method for ANA screening due to its high sensitivity. This method provides not only the detection of autoantibodies but also additional information about their potential target antigens through fluorescence patterns. However, indirect immunofluorescence results are not sufficient for the precise identification of specific autoantibodies and require additional confirmatory tests. At this stage, line blot and other immunoblot-based methods play a significant role. These technologies enable the determination of specific autoantibody profiles and facilitate the differential diagnosis of various systemic autoimmune diseases. Proper integration of screening and confirmation stages reduces false-positive results, increases diagnostic accuracy and optimizes clinical decision-making. At the same time, correct interpretation of ANA patterns and evaluation of autoantibodies in a clinical context are of particular importance. Low-titer ANA positivity and certain non-specific patterns may lead to misinterpretation. Therefore, integration of laboratory findings with clinical data is essential. In conclusion, the integrative application of screening and confirmation stages in autoimmune diagnostics allows for more reliable and clinically valuable results. This approach significantly improves early diagnosis, accurate differential assessment and effective patient management.